Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

JennyRowes Feb. 1 at 3:05 PM

$ABCL where can find insider sales information going back at least 2 years?

1 · Reply

Kaykay610 Jan. 31 at 1:34 PM

$ABCL not worried one bit!!! Everything will play out this year, even the doggy/kitty clincal field studies are set to finish this year. We bout to have solutions for mature aged lonely single women and they can bring all 19 cats we have something for everyone. Dmd treatment moved from active to complete so bring the step kids to

0 · Reply

Ed_Ng Jan. 30 at 9:26 PM

$ABCL I told them to take profit but they laughed at me. Now they cry 😿

0 · Reply

Ed_Ng Jan. 30 at 9:25 PM

$ABCL bear market or sideway, stock going down is acceptable. But during the last 3 years where there has been massive bull market but this stock is still lagging and trending down = no hope business

0 · Reply

Ckkung71 Jan. 30 at 9:24 PM

$ABCL Strange weak. 1/4 of the company. No bad news. Mostly good last month. Have the shorters so much power to make the moves like that?

1 · Reply

EdwardJL Jan. 30 at 9:13 PM

$ABCL Buy for the potential, stay for the drama. I remain

0 · Reply

DeMampCamp Jan. 30 at 9:11 PM

$ABCL Well, that was a nasty close! Thankfully it’s the weekend! Cheers, everyone!

0 · Reply

Plutten1973 Jan. 30 at 8:00 PM

$ABCL If u have patience u will be rewarded, only been here for about 5 years ,have patience for many years more!

0 · Reply

WenMoon9 Jan. 30 at 7:37 PM

$ABCL i really hope y'all sold at 4.50

3 · Reply

Odoji Jan. 30 at 7:05 PM

$ABCL we hanging strong considering they trying to liquidate the entire world 🤣

1 · Reply

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 9:16 PM EST - 17 days ago

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:00 AM EST - 20 days ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 6 weeks ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 7 weeks ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 1:37 PM EST - 7 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 22, 2025, 12:23 AM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 9:00 AM EST - 2 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 3 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 4 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 5 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 5 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 6 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 9 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 9 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 9 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 9 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 9 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 11 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

JennyRowes Feb. 1 at 3:05 PM

$ABCL where can find insider sales information going back at least 2 years?

1 · Reply

Kaykay610 Jan. 31 at 1:34 PM

0 · Reply

Ed_Ng Jan. 30 at 9:26 PM

$ABCL I told them to take profit but they laughed at me. Now they cry 😿

0 · Reply

Ed_Ng Jan. 30 at 9:25 PM

$ABCL bear market or sideway, stock going down is acceptable. But during the last 3 years where there has been massive bull market but this stock is still lagging and trending down = no hope business

0 · Reply

Ckkung71 Jan. 30 at 9:24 PM

$ABCL Strange weak. 1/4 of the company. No bad news. Mostly good last month. Have the shorters so much power to make the moves like that?

1 · Reply

EdwardJL Jan. 30 at 9:13 PM

$ABCL Buy for the potential, stay for the drama. I remain

0 · Reply

DeMampCamp Jan. 30 at 9:11 PM

$ABCL Well, that was a nasty close! Thankfully it’s the weekend! Cheers, everyone!

0 · Reply

Plutten1973 Jan. 30 at 8:00 PM

$ABCL If u have patience u will be rewarded, only been here for about 5 years ,have patience for many years more!

0 · Reply

WenMoon9 Jan. 30 at 7:37 PM

$ABCL i really hope y'all sold at 4.50

3 · Reply

Odoji Jan. 30 at 7:05 PM

$ABCL we hanging strong considering they trying to liquidate the entire world 🤣

1 · Reply

tradersunion353 Jan. 30 at 5:17 PM

$ABCL The stock has been in a steady downtrend since the conference. Really hoping we see this sell-off end at some point.

1 · Reply

AGC_Trader Jan. 30 at 3:56 PM

$ABCL A clear "bearish double top" formed on the daily chart. Let's see if it finds support here or at the bottom of the accumulation range (lower $3.30 s)

2 · Reply

JennyRowes Jan. 30 at 3:34 PM

$ABCL mag 7 are starting to crack and will pull down the whole market with small cap getting the worst of it… short term pain but a buying opportunity for us longs

2 · Reply

Ckkung71 Jan. 30 at 3:05 PM

$ABCL No more good news please we will lose another dollar😅

0 · Reply

Odoji Jan. 29 at 8:51 PM

$ABCL we getting stronger fam not long ago under these market conditions we’d probably tanked to low 3s high 2s which I wouldn’t really mind just a more parabolic run up. If Powell leaves in May next guy slash rates like crazy small caps run hard sector overdue timing could be perfecto

1 · Reply

Ed_Ng Jan. 29 at 7:26 PM

$ABCL $2.X coming for real

1 · Reply

Odoji Jan. 29 at 3:54 PM

$ABCL bout time to start adding again💉 plays like an ATM 💰🌴

0 · Reply

DeMampCamp Jan. 29 at 3:53 PM

$ABCL Love when this goes up you have people saying "What's reason for this move?" but when it goes down for no reason I don't see the same questions!

2 · Reply

tradersunion353 Jan. 29 at 3:36 PM

$ABCL Question for long-term investors: When’s the next major catalyst? From what I’ve researched, it looks like mid-2026. Hoping for some positive momentum — the stock hasn’t been performing well lately.

2 · Reply

Ed_Ng Jan. 29 at 2:36 PM

$ABCL I know. Don't ever listen to pumpers on green days ;-)

0 · Reply

Targhee Jan. 29 at 2:35 PM

$ABCL

0 · Reply

PorkchopSquats Jan. 29 at 12:29 PM

$ABCL $PRME

0 · Reply

Market Cap	1.08B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	4,313,700
Avg Vol	4,084,268
Day's Range	N/A - N/A
Shares Out	299.34M
Stochastic %K	2%
Beta	0.73
Analysts	Strong Sell
Price Target	$9.00